The global peptide therapeutics market represents one of the fastest-growing segments of the pharmaceutical industry, driven by GLP-1 receptor agonist dominance, expanding indications, and manufacturing innovations.
| Year | Market Size (USD) | Growth Rate | Key Driver |
|---|
| 2020 | ~$35B | — | Baseline |
| 2021 | ~$40B | +14% | COVID-19 impact |
| 2022 | ~$50B | +25% | GLP-1 expansion |
| 2023 | ~$65B | +30% | Obesity indication |
| 2024 | ~$85B | +31% | Wegovy/Mounjaro surge |
| 2025E | ~$110B | +29% | Oral GLP-1 launch |
| 2026E | ~$140B | +27% | Market expansion |
| 2027E | ~$170B | +21% | Maturation |
| 2028E | ~$200B | +18% | Biosimilar entry |
| 2030E | ~$260B | — | Market maturity |
| Period | CAGR |
|---|
| 2020–2024 | +25% |
| 2024–2028 | +24% |
| 2024–2030 | +20% |
| Segment | 2024 Revenue | % of Total | 2028 Projected |
|---|
| Diabetes | ~$45B | 53% | ~$90B |
| Obesity | ~$25B | 29% | ~$70B |
| Oncology | ~$6B | 7% | ~$15B |
| Rare diseases | ~$4B | 5% | ~$10B |
| Other therapeutic | ~$5B | 6% | ~$15B |
| Type | 2024 Revenue | % of Total |
|---|
| GLP-1 agonists | ~$55B | 65% |
| Insulins | ~$20B | 24% |
| Other peptide hormones | ~$5B | 6% |
| GnRH analogs | ~$3B | 3% |
| Other | ~$2B | 2% |
| Route | 2024 Revenue | % of Total |
|---|
| Subcutaneous injection | ~$65B | 76% |
| Intravenous | ~$8B | 9% |
| Oral | ~$7B | 8% |
| Intranasal | ~$3B | 4% |
| Other | ~$2B | 3% |
| Rank | Company | Key Peptides | 2024 Revenue |
|---|
| 1 | Novo Nordisk | Semaglutide, Liraglutide, Insulin | ~$45B |
| 2 | Eli Lilly | Tirzepatide, Dulaglutide, Insulin | ~$30B |
| 3 | Sanofi | Insulin Glargine, Lixisenatide | ~$5B |
| 4 | AstraZeneca | Exenatide (legacy) | ~$2B |
| 5 | Takeda | Liraglutide (legacy) | ~$1B |
| Company | Focus | Pipeline Peptides |
|---|
| Amgen | Obesity | MariTide (monthly GLP-1) |
| Pfizer | Oral GLP-1 | Danuglipron |
| Roche | Obesity | CT-996 (oral) |
| Viking Therapeutics | Obesity | VK2735 (dual agonist) |
| Structure Therapeutics | Oral GLP-1 | GSBR-1290 |
| Zealand Pharma | Metabolic | Petrelintide |
| Zealand Pharma | Rare disease | Dasiglucagon |
| Crinetics Pharmaceuticals | Rare disease | Paltusotine |
| Company | Focus | Products |
|---|
| Biocon | Insulin biosimilars | Insulin Glargine |
| Viatris | Peptide generics | Various |
| Dr. Reddy’s | Peptide generics | Various |
| Sandoz | Biosimilars | Various |
| Product | Company | Revenue | Market Share |
|---|
| Ozempic (semaglutide SC) | Novo Nordisk | ~$20B | ~36% |
| Wegovy (semaglutide SC obesity) | Novo Nordisk | ~$8B | ~15% |
| Mounjaro (tirzepatide T2D) | Eli Lilly | ~$12B | ~22% |
| Zepbound (tirzepatide obesity) | Eli Lilly | ~$8B | ~15% |
| Rybelsus (semaglutide oral) | Novo Nordisk | ~$4B | ~7% |
| Trulicity (dulaglutide) | Eli Lilly | ~$3B | ~5% |
| Formulation | Revenue | % |
|---|
| Semaglutide injectable | ~$32B | 58% |
| Tirzepatide injectable | ~$20B | 36% |
| Semaglutide oral | ~$4B | 7% |
| Company | Peptide Manufacturing Revenue | Capabilities |
|---|
| Bachem | ~$800M | SPPS, GMP |
| Corden Pharma | ~$500M | SPPS, formulation |
| PolyPeptide Group | ~$400M | SPPS, API |
| Thermo Fisher | ~$300M | CDMO services |
| Reagent Category | 2024 Market | Key Suppliers |
|---|
| Amino acid derivatives | ~$1.2B | Novabiochem, Sigma |
| Resins (Wang, Rink) | ~$300M | CEM, Gyros |
| Coupling reagents | ~$200M | Sigma, TCI |
| Solvents (DMF, NMP) | ~$400M | BASF, Evonik |
| Peptide | Synthesis Cost/g | Purification Cost/g | Total COGS/g |
|---|
| Insulin (recombinant) | $100–200 | $50–100 | $200–400 |
| Semaglutide (SPPS) | $500–1,000 | $200–500 | $800–1,500 |
| BPC-157 (SPPS) | $200–400 | $100–200 | $300–600 |
| GLP-1 (SPPS) | $300–600 | $150–300 | $500–900 |
| Peptide | Company | Indication | Status |
|---|
| MariTide | Amgen | Obesity | Phase III |
| Survodutide | Boehringer | MASH, Obesity | Phase III |
| Orforglipron | Eli Lilly | Obesity | Phase III |
| Danuglipron | Pfizer | Obesity | Phase III |
| CT-996 | Roche | Obesity | Phase II |
| Petrelintide | Zealand | Obesity | Phase III |
| Paltusotine | Crinetics | Acromegaly | Phase III |
| Scenario | 2028 Market Size | Key Assumption |
|---|
| Conservative | $150B | Limited new entries |
| Base case | $200B | 2–3 new blockbuster launches |
| Bullish | $250B | 4+ new entries, expanded indications |
- Obesity epidemic: Growing global prevalence driving demand for GLP-1 agonists
- Diabetes burden: Expanding T2D patient population
- Indication expansion: GLP-1 agonists for MASH, CKD, heart failure, sleep apnea
- Oral formulations: Improved patient convenience and adherence
- Manufacturing scale: SPPS improvements reducing cost of goods
- Biosimilar competition: Post-patent expiration price competition
- Manufacturing capacity: Demand exceeding supply (GLP-1 shortage)
- Pricing pressure: Payer pushback on high drug costs
- Biosimilar threat: Post-patent erosion of blockbuster revenues
- Safety signals: Long-term cardiovascular and safety data requirements
- Competition: Multiple companies developing GLP-1 agonists
The peptide therapeutics market is experiencing unprecedented growth driven by GLP-1 receptor agonists for diabetes and obesity. Novo Nordisk and Eli Lilly dominate with >80% market share. The market is projected to reach $200–250B by 2028, with oral peptides and next-generation multi-agonists driving expansion. Manufacturing capacity, pricing, and biosimilar competition are the key challenges for sustaining growth.
